Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

This multicenter trial evaluated the efficacy of combining alemtuzumab (Campath 1-H) to standard CHOP for peripheral T-cell lymphomas. Among 24 evaluable patients, the complete response rate was 17/24 (71%) using 8 cycles of CHOP plus 30 mg of Campath monthly.

CHOP-Campath for PTCL